In a historic shift, the U.S. moves to reclassify marijuana as a less dangerous drug, according to AP sources. Currently, cannabis is classified along with drugs like heroin and LSD. However, the Biden administration is expected to reschedule it in a category that reflects its lower risk.
The DEA has proposed moving marijuana from its current status as a Schedule I drug to Schedule III under the Controlled Substances Act. This change has not yet taken effect but could have significant implications for drug policy and research.
Updated reports indicate that the Drug Enforcement Administration (DEA) will reclassify cannabis as a Schedule III drug, marking a significant departure from its previous categorization. This move reflects a growing recognition of the potential medical benefits of marijuana.
The federal government's plan to reclassify marijuana would acknowledge its potential as a prescribable substance, overturning its previous designation as highly dangerous and addictive with no medical use. This change could pave the way for increased research and access to medical cannabis.
Sources have revealed that the DEA is planning to recommend reclassifying marijuana as a less dangerous drug, shifting it from Schedule I to Schedule III. This decision could have wide-ranging implications for drug policy and public perception of marijuana.
The US Justice Department has recommended that cannabis be reclassified as less risk, a move that could benefit the growing legal cannabis industry. This decision reflects a shift in attitudes towards marijuana and its potential benefits.
In a major shift, marijuana could be reclassified as a less dangerous drug in the U.S., according to reports. This potential change raises questions about the future of marijuana regulation and research.
